The recent news below states that the new BSSP/Canteck Pharma, Inc. has initial deployment for sales of the specific Irreversible Pepsin Fraction (IPF) for Cancer indication product and treatment programs to Mexico are now in process with four (4) hospitals positioned and in process of licensing requirements which have been submitted. Canteck is positioned to oversee the development, manufacturing and commercialization processes for our lead product to be the Irreversible Pepsin Fraction (IPF) specific to the Cancer indication, with options for other indications:
http://finance.yahoo.com/news/reve-acquires-e...00687.html

Significant BSSP/Canteck Pharma, Inc. Slideshow
http://www.cantechpharma.com/cancer-treatment/

http://www.cantechpharma.com/wp-content/uploa...n-2015.pdf